Wordt geladen...
ALK阳性非小细胞肺癌靶向治疗研究进展
The rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. The first-in-class ALK tyrosine kinase inhibitor, crizotinib, can effectively target these tumors represent a significant advance in the evolution of personalized medicine for...
Bewaard in:
| Gepubliceerd in: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
中国肺癌杂志编辑部
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000407/ https://ncbi.nlm.nih.gov/pubmed/25539610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2014.12.05 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|